Biomimeting ultra-small lipid nanoconstructs for glioblastoma treatment: A computationally guided experimental approach.

International Journal of Pharmaceutics
Maria MendesCarla Vitorino

Abstract

Ultra-small nanostructured lipid carriers (usNLCs) are stable, biocompatible and biodegradable colloidal systems, claiming a broad set of advanced features suitable for cancer drug delivery. To unleash their potential in glioblastoma research and therapy, we have developed an usNLC prototype able to co-encapsulate atorvastatin calcium and curcumin, as repurposed drugs previously screened from molecular dynamics simulations. The novelty not only relies on the drug repositioning approach, but also on a robust computational methodology utilized for formulation optimization, under the umbrella of multivariate analysis and full factorial designs. A coating procedure with red blood cell membranes is ultimately hypothesized, aiming at integrating the biomimetic concept into usNLCs for glioblastoma therapeutics. The formulation composition and process parameters, that demonstrated a high-risk level for the final quality and performance of the usNLCs, include the solid:liquid lipid ratio, type and concentration of liquid lipids and surfactants, along with the type of production method. Particles with an average diameter of ca. 50 nm, and a polydispersity index lower than 0.3 were produced, exhibiting high stability, up-scalability, drug...Continue Reading

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Related Papers

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
João BassoCarla Vitorino
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Maria MendesCarla Vitorino
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Issan ZhangDusica Maysinger
© 2021 Meta ULC. All rights reserved